CPIX
Cumberland Pharmaceuticals Inc
7.40$
-1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.8% | -0.3% | -3.7% | -2.3% | -1.5% | -7.5% | -2.9% | -3.0% | +16.6% | -7.6% | -11.4% | |
| – | -14.5% | +1.4% | -1.7% | -1.0% | +3.5% | -12.6% | -2.1% | -4.1% | +23.8% | -11.5% | +2.6% | |
| – | -1.0% | +1.2% | -6.5% | +0.7% | +2.9% | -15.9% | +6.5% | -5.5% | -24.7% | -3.8% | -64.9% | |
| – | -1.0% | +1.2% | -6.5% | +0.7% | +2.9% | -15.9% | +6.5% | -5.5% | -24.7% | -3.8% | -64.9% | |
| – | -22.7% | +9.1% | +9.1% | -2.7% | +3.5% | -10.4% | -1.6% | +1.1% | +62.5% | -15.8% | -5.9% | |
| – | -46.8% | -6.1% | -0.6% | +4.8% | -11.3% | +2.5% | -21.4% | -8.9% | +112.1% | -12.4% | -99.5% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | |
| – | -16.6% | -4.8% | -4.9% | -5.1% | -7.4% | -5.5% | -5.9% | -6.1% | -6.5% | -8.8% | -99.7% | |
| – | +0.8% | +3.4% | -3.4% | -0.4% | +1.5% | -21.6% | -3.3% | -0.3% | +30.4% | -4.9% | -7.9% | |
| – | +2.4% | -5.6% | -6.3% | +25.6% | +1.7% | -19.3% | -6.1% | +1.4% | +51.2% | -6.1% | +2.0% | |
| – | +4.1% | +4.1% | +4.0% | +1,593.5% | -14.5% | -93.2% | +4.0% | +4.0% | +16.5% | +3.7% | +3.7% | |
| – | +29.8% | -6.9% | -4.3% | -3.6% | +15.4% | +0.1% | -3.5% | +2.9% | +34.2% | -10.9% | +18.2% | |
| – | -1.1% | +25.8% | +0.0% | -37.2% | +0.7% | -48.5% | +0.0% | +0.0% | +0.0% | +0.0% | – | |
| – | -17.7% | -7.1% | -4.1% | -6.0% | -7.8% | +25.4% | -2.3% | -6.7% | -4.7% | -13.0% | -19.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.8% | -0.5% | +0.1% | -0.5% | -0.6% | +9.2% | -2.0% | 0.0% | +0.0% | +0.0% | +0.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.